Life Sciences News | BioTuesdays by Kilmer Lucas IR

Developments

Palisade Bio doses first patient in Phase 3 post-op return of bowel function trial

Palisade Bio (NASDAQ:PALI) dosed the first patient in its Phase 3 study evaluating LB1148 to accelerate the return of bowel function in adult patients undergoing gastrointestinal surgery. “With what we believe to be a...

August 17, 2022

Developments

Blue Water to explore development of VLP monkeypox vaccine

Blue Water Vaccines (NASDAQ:BWV) plans to explore the potential to develop a novel monkeypox vaccine using its norovirus shell and protrusion virus-like particle (VLP) platform. The company’s shell and protrusion...

August 17, 2022

Executive Moves

Verséa Holdings names Rob Sambursky as president to lead ophthalmic expansion

Verséa Holdings appointed Rob Sambursky, M.D., as president to support its corporate strategy and operations as well as lead the company’s expansion into the ophthalmic market. Verséa recently launched a new business...

August 16, 2022

Executive Moves

Titan Pharma names new CEO, expands board

Titan Pharmaceuticals (NASDAQ:TTNP) appointed Activist Investing’s David Lazar as interim chairman and CEO, with a mandate to lead Titan’s continuing review of strategic alternatives. He succeeds Marc Rubin, M.D...

August 16, 2022

Markets

Maxim cuts Aridis Pharma to hold

Maxim Group downgraded Aridis Pharmaceuticals (NASDAQ:ARDS) to “hold” from “buy” and removed its price target, citing capital concerns and key clinical programs. The stock closed at $2.19 on Aug. 15. In a 10-Q report...

August 16, 2022

Markets

Dawson James cuts Aditxt Therapeutics PT to $1 from $6

Dawson James Securities slashed its price target for Aditxt Therapeutics (NASDAQ:ADTX) to $1 from $6, but maintained a “buy” rating, noting that cash is tight and a capital raise is expected. The stock closed at 17...

August 16, 2022

Developments

iBio updates development of next-gen COVID-19 vaccine candidate

iBio (NYSEA:IBIO) provided an update on IBIO-202, its next-generation vaccine candidate under development for multi-variant COVID-19 disease. Unlike first-generation COVID vaccines that seek to provide immunity by...

August 16, 2022

Developments

First patients treated with LENSAR’s ALLY cataract treatment

The first commercial cases of the LENSAR (NASDAQ:LNSR) ALLY Adaptive Cataract Treatment System were performed by Robert Weinstock, M.D. at The Eye Institute of West Florida. Dr. Weinstock performed 15 laser-assisted...

August 16, 2022

Markets

Stifel cuts IDEAYA to hold on skepticism of MAT2A cancer program

Stifel downgraded IDEAYA Biosciences (NASDAQ:IDYA) to “hold” from “buy” and reduced its price target to $13 from $16 “on the belief that it’s difficult to gain high conviction in the MTAP/MAT2A thesis (we ascribe...

August 15, 2022

Markets

Cantor starts Mereo BioPharma at OW; PT $4

Cantor Fitzgerald initiated coverage of Mereo BioPharma (NASDAQ:MREO) with an “overweight” rating and $4 price target. The stock closed at $1.15 on Aug. 11. Mereo is a clinical-stage biopharmaceutical company that is...

August 12, 2022

Markets

BTIG cuts Pear Therapeutics PT to $5 on Q2 results

BTIG reduced its price target for Pear Therapeutics (NASDAQ:PEAR) to $5 from $11 but maintained its “buy” rating after the company missed second quarter revenue consensus and lowered 2022 revenue guidance. The stock...

August 12, 2022

Markets

Cantor cuts TerrAscend to neutral on model update post Q2 miss

Cantor Fitzgerald downgraded TerrAscend (OTCQX:TRSSF) to “neutral” from “overweight” and reduced its price target to $2.85 from $6.45 on lower estimates and sectoral derating. The stock closed at $2.40 on Aug. 11...

August 12, 2022

Palisade Bio doses first patient in Phase 3 post-op return of bowel function trial

Blue Water to explore development of VLP monkeypox vaccine

Verséa Holdings names Rob Sambursky as president to lead ophthalmic expansion

Titan Pharma names new CEO, expands board

Maxim cuts Aridis Pharma to hold

Dawson James cuts Aditxt Therapeutics PT to $1 from $6

iBio updates development of next-gen COVID-19 vaccine candidate

First patients treated with LENSAR’s ALLY cataract treatment

Stifel cuts IDEAYA to hold on skepticism of MAT2A cancer program

Cantor starts Mereo BioPharma at OW; PT $4

BTIG cuts Pear Therapeutics PT to $5 on Q2 results

Cantor cuts TerrAscend to neutral on model update post Q2 miss

General

More